Spyre Therapeutics (SYRE) Notes Payables (2023 - 2026)

Spyre Therapeutics (SYRE) has 4 years of Notes Payables data on file, last reported at $50.3 million in Q1 2026.

• Quarterly Notes Payables rose 17.4% year-over-year to $50.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $50.3 million (up 17.4% YoY) and the FY2025 annual result came in at $22.8 million, down 9.01% from the prior year.
• Notes Payables rose to $50.3 million in Q1 2026, from $22.8 million in the prior quarter.
• In the past five years, Notes Payables ranged from a high of $59.9 million in Q2 2025 to a low of $1.4 million in Q4 2023.
• A 4-year average of $22.6 million and a median of $21.8 million in 2023 frame the typical range for Notes Payables.
• Annual changes were most pronounced in 2024 — Notes Payables tumbled 87.31% — and 2025, when it jumped 2168.94%.
• Tracing SYRE's Notes Payables over 4 years: stood at $1.4 million in 2023, then soared by 1704.32% to $25.1 million in 2024, then slipped by 9.01% to $22.8 million in 2025, then surged by 120.25% to $50.3 million in 2026.
• The last three Notes Payables figures came in at $50.3 million (Q1 2026), $22.8 million (Q4 2025), and $11.0 million (Q3 2025), per Business Quant data.